AU2014218903A1 - Methods and compositions of treating and preventing intestinal injury and diseases related to tight junction dysfunction - Google Patents

Methods and compositions of treating and preventing intestinal injury and diseases related to tight junction dysfunction Download PDF

Info

Publication number
AU2014218903A1
AU2014218903A1 AU2014218903A AU2014218903A AU2014218903A1 AU 2014218903 A1 AU2014218903 A1 AU 2014218903A1 AU 2014218903 A AU2014218903 A AU 2014218903A AU 2014218903 A AU2014218903 A AU 2014218903A AU 2014218903 A1 AU2014218903 A1 AU 2014218903A1
Authority
AU
Australia
Prior art keywords
glycerophosphate
composition
subject
exercise
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014218903A
Other languages
English (en)
Inventor
Alan E. Kligerman
Margaret T. Weis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PRELIEF Inc
Original Assignee
PRELIEF Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PRELIEF Inc filed Critical PRELIEF Inc
Publication of AU2014218903A1 publication Critical patent/AU2014218903A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
AU2014218903A 2013-02-20 2014-02-20 Methods and compositions of treating and preventing intestinal injury and diseases related to tight junction dysfunction Abandoned AU2014218903A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361766976P 2013-02-20 2013-02-20
US61/766,976 2013-02-20
US201361827080P 2013-05-24 2013-05-24
US61/827,080 2013-05-24
US201361897672P 2013-10-30 2013-10-30
US61/897,672 2013-10-30
PCT/US2014/017408 WO2014130678A2 (en) 2013-02-20 2014-02-20 Methods and compositions of treating and preventing intestinal injury and diseases related to tight junction dysfunction

Publications (1)

Publication Number Publication Date
AU2014218903A1 true AU2014218903A1 (en) 2015-09-17

Family

ID=50240015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014218903A Abandoned AU2014218903A1 (en) 2013-02-20 2014-02-20 Methods and compositions of treating and preventing intestinal injury and diseases related to tight junction dysfunction

Country Status (9)

Country Link
US (1) US20150374725A1 (https=)
EP (1) EP2958567A2 (https=)
JP (1) JP2016509059A (https=)
KR (1) KR20150141943A (https=)
CN (1) CN105163740A (https=)
AU (1) AU2014218903A1 (https=)
HK (1) HK1219868A1 (https=)
MX (1) MX2015010765A (https=)
WO (1) WO2014130678A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
EP3345591A1 (en) * 2017-01-06 2018-07-11 Oystershell NV Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993837A (en) * 1959-07-13 1961-07-25 Frosst & Co Charles E Enteric coated tablets
US5665415A (en) 1995-07-26 1997-09-09 Akpharma Inc. Composition and method for increasing the pH of acid foods
US20020099037A1 (en) * 2001-01-19 2002-07-25 Akpharma, Inc. Method for alleviating syndromes and conditions of discomfort of the mammalian intestinal and genito-urinary tracts
US7402323B2 (en) 2002-08-21 2008-07-22 Akpharma, Inc. Compositions and methods for treating skin conditions
US20070155664A1 (en) * 2003-07-04 2007-07-05 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2008100980A1 (en) * 2007-02-14 2008-08-21 Prelief Inc. Methods for treating or preventing inflammation using a glycerophosphate salt
US20080220084A1 (en) * 2007-03-09 2008-09-11 Pfantastic Medical Research Institute, Llc Combination therapy for alleviating pain-related conditions
EP2180895A4 (en) * 2007-08-30 2012-04-11 Prelief Inc METHODS FOR IMPROVING THE HEALING OF ORAL INJURY USING GLYCEROPHOSPHATE SALT
WO2009052489A2 (en) * 2007-10-19 2009-04-23 Alba Therapeutics Corporation Novel inhibitors of mammalian tight junction opening

Also Published As

Publication number Publication date
WO2014130678A2 (en) 2014-08-28
KR20150141943A (ko) 2015-12-21
EP2958567A2 (en) 2015-12-30
MX2015010765A (es) 2016-05-09
WO2014130678A3 (en) 2014-11-20
CN105163740A (zh) 2015-12-16
US20150374725A1 (en) 2015-12-31
JP2016509059A (ja) 2016-03-24
HK1219868A1 (zh) 2017-04-21

Similar Documents

Publication Publication Date Title
US10307386B2 (en) Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
KR100553294B1 (ko) 역류 억제제
RS55769B1 (sr) Kompozicije tapentadola
KR102194174B1 (ko) 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
CN111328279A (zh) 口服利福霉素sv组合物
MX2008005936A (es) Composiciones para regular trastornos metabolicos y metodos de uso de las mismas.
KR20080106991A (ko) 내장통 치료용 옥시코돈의 사용
US20150374725A1 (en) Methods and compositions for treating and preventing intestinal injury and diseases related to tight junction dysfunction
Ishida et al. Effect of acetaminophen, a cyclooxygenase inhibitor, on Morris water maze task performance in mice
CN120112280A (zh) 用于口服递送的组合物
US10537528B2 (en) Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
ES2906316T3 (es) Formas farmacéuticas de dosificación oral para el tratamiento de trastornos metabólicos y enfermedades relacionadas mediante la liberación orquestada de enterocinas
CZ20032256A3 (en) Medicinal compositions comprising diclofenac and ornoprostil
Radi Comparative pathophysiology and toxicology of cyclooxygenases
Warlick IV et al. Role of vesicular monoamine transporter-2 for treating attention deficit hyperactivity disorder: a review
US20230088240A1 (en) Accelerating the drying rate of softgel capsules
US20230355596A1 (en) Compositions and methods of using nmdar inhibitors and kinase inhibitors to treat liver cancer
WO2025008449A1 (en) Use of tryptophan hydroxylase 1 (tph1) inhibitors for the treatment of atherosclerosis
Özgüney Conventional and novel pharmaceutical dosage forms on prevention of gastric ulcers
KR20190076809A (ko) 위장 질환용 조성물
TW202200127A (zh) 用於治療化學療法引起的腹瀉之方法及組合物
AU2014233607A1 (en) Methods of Treating Non-Alcoholic Steatohepatitis (NASH) Using Cysteamine Products
HK1141945B (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
HK1189802B (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application